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Summary B-cell high-grade lymphomas are heterogeneous in terms of histology, clinical presentation, treat-
ment response and prognosis. As bcl-2 and p53 gene deregulations are frequencly involved in several types of
lymphoid malignancies, we aimed our investigation at the study of the relation between bcl-2 and p53
expression and survival probability in a group of 119 patients with B-cell high-grade lymphoma. These were
obtained from the Virgen de la Salud Hospital, Toledo, Spain (73 cases), John Radcliffe Hospital, Oxford, UK
(31 cases), and the Istituto Nazionale dei Tumori, Milan, Italy (15 cases). The relation between bcl-2 protein
expression and survival was small, depending on the primary localisation of the tumour (in lymph node of
mucosae), and lacked a significant correlation with overall survival. In contrast with this, p53 expression was
related to survival probability in our series, this relation being both significant and independent of histological
diagnosis. p53-positive patients showed a sudden decrease in life expectancy in the first months after diagnosis.
Multivariant regression analysis confirmed that the only parameters significantly related with survival were
extranodal origin, which is associated with a better prognosis, and p53 expression, which indicates a poor
prognosis. Simultaneous expression of bcl-2 and p53 was associated with a poorer prognosis than p53 alone.
This is particularly significant for large B-cell lymphomas presenting in lymph nodes. The cumulative poor
effect of both p53 and bcl-2 in large B-cell lymphomas, which is more significant in nodal tumours, could
confirm the existence of a multistep genetic deregulation in non-Hodgkin's lymphoma. This indicates that the
genetic mechanisms controlling apoptosis and their disregulation are critical steps in the progression of
lymphomas.
Large-cell lymphomas (LCL) are heterogeneous in terms of
histology, clinical presentation, treatment response and prog-
nosis. Although some clinical parameters (age, stage, histo-
logical diagnosis, lactate dehydrogenase, tumour burden)
may allow survival time to be predicted, the genetic and
molecular basis of the progression of the disease and its
response to chemotherapy have yet to be elucidated (Velas-
quez et al., 1989; Coiffier et al., 1991). Although the 14;18
translocation has been found in 10-25% of LCL, and 8;14
translocation in 10% of LCL and 90% of Burkitt's lym-
phomas, specific chromosomal changes have not yet been
found in most cases of B-cell high-grade lymphoma
(Aisenberg et al., 1988; Raghoebier et al., 1991).
The 14;18 translocation juxtaposes the immunoglobulin
heavy-chain gene onto the bcl-2 oncogene on chromosome
18, giving rise to activation of the bcl-2 gene, with increased
production of mRNA and protein (Seto et al., 1988). bcl-2
protein has been shown to induce cell survival by blocking
programmed cellular death in transfected cell lines (Hocken-
berry et al., 1990). bcl-2 expression can be independent of
t(14;18) (Pezzella et al., 1990), it being possible to induce
bcl-2 expression by latent Epstein-Barr virus genes (Hender-
son et al., 1991; Finke et al., 1992). bcl-2 expression has been
found in a high percentage of large B-cell non-Hodgkin
lymphomas (Pezzella et al., 1990; Villuendas et al., 1991;
Zutter et al., 1991).
p53 is a suppressor gene, involved in the transcription of
genes that negatively control cell proliferation. Protein detec-
tion by immunocytochemistry has been related to gene muta-
tion, which stabilises the protein and prevents its degradation.
However, further studies have confirmed that activated lym-
phoid cells may express p53, expression being dependent on
cell cycle phase (M. Sanchez-Beato, submitted). p53 muta-
tions have been described in Burkitt's lymphoma (Farrell et
al., 1991; Gaidano et al., 1991; Wiman et al., 1991), and
adult T-cell leukaemia/lymphoma (ATLL) (Ceserman et al.,
1992) but p53 protein detection has been reported in other
different types of B-cell high-grade lymphoma (Doglioni et
al., 1991; Villuendas et al., 1992; Pezzella et al., 1993). A
recent study relates p53 mutation to disease progression in
B-cell lymphoma (Ichikawa et al., 1992).
Both p53 and bcl-2 genes have been described as related to
the genetic control of apoptosis, or programmed cell death
(Hockenberry et al., 1990; Clarke et al., 1993; Fritsche et al.,
1993; Hall et al., 1993; Lowe et al., 1993). The aim of this
investigation was the study of both bcl-2 and p53 expression,




Fresh frozen tissue samples from 119 patients with B-cell
high-grade lymphoma were obtained through the routine
histopathological services of the Virgen de la Salud Hospital,
Toledo, Spain (73 cases), John Radcliffe Hospital, Oxford,
UK (31 cases), and Istituto Nazionale dei Tumori, Milan,
Italy (15 cases). Diagnosis was based on examination of
paraffin-embedded material stained by haematoxylin and
eosin, and on the immunostaining of frozen sections accord-
ing to routine techniques. Eighty-eight cases were classified as
nodal diffuse large B-cell lymphoma (centroblastic or
immunoblastic); 25 as mucosa-associated lymphoid tissue
(MALT) large B-cell lymphoma in gastrointestinal tract or
lung, without lymph node infiltration beyond regional
lymphadenopathies; and 10 as Burkitt's lymphoma. Classi-
fication criteria were used according to the Kiel update
classification (Lennert & Feller, 1990).
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Patients
Patients were from the Department of Oncology, Virgen de
la Salud Hospital, Toledo, Spain; from the Radiotherapy
Department, Churchill Hospital, Oxford, UK; and from the
Istituto Nazionale dei Tumori, Milan, Italy. They were
treated with chemo- and/or radiotherapy. Clinical follow-up
ranged from less than 1 month to 190 months. Fifty-six
patients were followed up until death, 60 are still alive and
two were lost to follow-up after 32 and 57 months.
Immunohistochemistry
Frozen sections were immunostained using the alkaline phos-
phatase-anti-alkaline phosphatase (APAAP) method (Cordell
et al., 1984), with the anti-bcl-2 monoclonal antibody bcl-2
100 (Pezzella et al., 1990) raised to a synthetic peptide. For
p53 detection the anti-p53 monoclonal antibody PAb 1801
was used. This specifically detects human wild-type and
mutant p53 (Banks et al., 1986), recognising the N-terminal
epitope of the protein.
Positive staining of small lymphocytes for bcl-2 provided
an internal control for bcl-2 staining. Cases in which small
lymphocytes were bcl-2 negative were excluded. For p53,
simultaneous staining of known p53+ cases was employed.
The incubation of parallel slides omitting the first antibody
was performed as a negative control.
Statistical analysis
Actuarial survival curves were plotted using the Kaplan and
Meier (1958) method. Statistical significance was calculated
using the log-rank test (Peto et al., 1975) for univariate
analysis. The Cox (1972) regression model was used for
multivariate analysis and calculation of the hazards ratio and
its confidence interval. Statistical analysis was carried out on
all series and the nodal lymphomas. No analysis was per-
formed solely on the MALT and Burkitt lymphomas, with
the exception of multivariate analysis, as the series were too
small.
Results
All the results of statistical analysis are shown in Tables I to
IV.
bcl-2protein expression
Immunostaining for bcl-2 was performed on 115 cases, the
results of which are given in Table I. Two patterns of stain-
ing were observed: in 64 cases the great majority of neoplas-
tic cells were bcl-2 positive in cytoplasm, whereas in the
remaining 51 cases lymphomatous cells were negative. As is
shown in Tables I and II, the expression of bcl-2 is distri-
buted according to histological classification, being frequent
in nodal and rare in mucosal large B-cell lymphomas (P<
0.001). The survival curve for bcl-2-positive cases shows that
patients with these tumours have a progressive decrease in
life expectancy, without a definite plateau (Figure 1). Never-
theless, bcl-2 expression does not appear to be related to
survival in a statistically significant way over the entire group
of B-cell high-grade lymphomas (P = 0.143) (Table III).
p53 protein expression
Immunostaining for p53 was done on 93 cases: 24 positive
cases and 69 negative cases were found (Table I). Two pat-
terns of staining were observed: in positive cases the great
majority of neoplastic cells showed nuclear staining, whereas
in the remaining 69 cases cells were negative, with either just
a few scattered positive cells or none at all.
The expression of p53 is not dependent on nodal and
mucosa localisation (P = 0.9356), although it is more fre-
quent in Burkitt's lymphoma, where it was found in 62.5%
of cases (P = 0.0179).
Statistical analysis of the survival curve shows that p53
expression appears to be significantly related to survival,
taking the whole group of B-cell high-grade lymphomas into
consideration (P = 0.0125), with a relative risk confidence
interval of 1.15-3.97 (Table III). p53+ tumours appear to
present a sudden decrease in life expectancy during the
months immediately following diagnosis, which then pro-
gresses to stabilisation (Figure 2).
bcl-2 andp53 protein expression
In 89 cases staining for both bcl-2 and p53 was available, and
the results are shown in Table II. Survival curves (Figure 3)
on both the whole series and for nodal diffuse lymphoma
show a shorter survival time for patients with a lymphoma
expressing both proteins compared with those with a lym-
phoma expressing only one or neither. This relationship is
more significant in nodal diffuse large B-cell lymphomas that
coexpress the two proteins. In this group of patients (10
cases), 5-year survival expectancy (10.0%) is shorter than for
those patients with lymphomas that express only one or
neither of the proteins (48%). The statistically significant
association with poorer prognosis (P = 0.006) is supported by
the confidence interval of the relative risk ratio, which at
95% ranges from 1.27 to 6.00.
Multivariable study
To clarify the specific value of bcl-2 and p53, independently
of the diagnosis, the survival impact of histological diagnosis
combined with p53 and bcl-2 expression was analysed. The
survival probability of Burkitt cases was used as a reference.
MALT lymphomas have a rather better prognosis, although
this finding is not statistically significant. p53 expression
indicates a poor prognosis (Table IV), independently of the
other factors analysed (P = 0.019). In a separate assay, the
impact of simultaneous p53 and bcl-2 expression was assess-
ed, the relative risk being equivalent to the addition of p53
and bcl-2 relative risks.
Discussion
Table I Expression of bcl-2 and p53
classification
according to histological
Large B-cell Large B-cell
nodal MALT Burkitt Total
Bcl-2
Negative 26 (31%) 18 (82%) 7 (70%) 51 (44%)
Positive 57 (69%) 4 (18%) 3 (30%) 64 (56%)
Total 83 22 10 115
p53
Negative 54 (77%) 12 (80%) 3 (37%) 69 (74%)
Positive 16 (23%) 3 (30%) 5 (63%) 24 (26%)
Total 70 15 8 93
The distribution of both bcl-2 and p53 proteins in reactive
lymph nodes and lymphomas has already been described
(Pezzella et al., 1990, 1993; Villuendas et al., 1991, 1992). The
Table II Combined bcl-2 and p53 expression
Large B-cell Large B-cell
Immunostaining nodal MALT Burkitt Total
bcl-2+, p53+ 11 2 1 14
bcl-2+, p53- 33 1 1 35
bcl-2-, p53- 20 9 2 31
bcl-2-, p53+ 4 1 4 9
Total 68 13 8 89p53 AND bcl-2 EXPRESSION IN LYMPHOMA 339
Table III Survival of 118 patients with B-cell high-grade non-Hodgkin's lymphoma according to bcl-2 and p53 expression
Immunostaining Relative risk 95%
Histology Number ofpatients 5-year survival (%) X square P-value Relative risk confidence interval
bcl-2+ bcl-2- bcl-2+ bcl-2-
Total nodal 64 51 40.2 51.5 2.10 0.143 1.49 0.86-2.59
57 26 35.0 45.8 1.48 0.222 1.52 0.76-3.04
p53+ pS3- pS3+ pS3-
Total nodal 24 69 33 54 4.97 0.0125 2.13 1.15-3.97
16 54 31.5 48 2.09 0.1438 1.70 0.82-3.59
bcl-2, p53 Others bcl-2, p53 Others
Total nodal 14 75 23.2 51.2 5.50 0.018 2.20 1.11-4.42
11 57 10.0 48.9 7.43 0.006 2.76 1.27-6.00
Table IV Relation between survival time and histological diagnosis,
p53 and bcl-2 expression in high-grade B-cell lymphomas, multivariate
analysis (Cox)
Relative risk
Relative risk P-value confidence interval
MALT 0.41 0.223 0.099- 1.726
Nodal 1.05 0.924 0.354-3.127
Burkitt I
bcl-2 1.28 0.541 0.671 -2.447
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results are similar to those found in this series, in which bcl-2
expression is more frequently detected in large B-cell lym-
phomas of nodal origin, and rarely in cases of Burkitt and
MALT lymphoma.
Deregulation of the bcl-2 gene represents a primary patho-
genic event in the generation of some types of lymphoma,
mainly those associated with a 14;18 translocation. bcl-2
activation could condition progression of a neoplasia through
different mechanisms. bcl-2 expression in cell lines can confer
a survival advantage on tumoral cells, through the inhibition
of apoptosis or programmed cellular death (Hockenberry et
al., 1990). It has also been suggested that bcl-2 activation,
through cooperation with c-myc or other oncogenes, may
lead to drug resistance by blocking apoptosis (Fanidi et al.,
1992).
The prognostic significance of bcl-2 expression has already
been explored in follicular CB-CC lymphoma, in which bcl-2-
positive and -negative tumours have a similar prognosis
(Pezzella et al., 1992). In our series, patients with bcl-2+
tumours showed a progressive decrease in survival proba-
bility, with some late relapses being found. This is different
from findings in cases of bcl-2-negative high-grade B-cell
lymphomas, which show a definite plateau after an initial fall
in survival probability. However, the relation between bcl-2
protein expression and survival seems to be small, depending
on the diagnosis (nodal or MALT). It also lacks a significant
Figure 3 Relation between bcl-2 and p53 combined expression
and survival probability. Comparison of cases with simultaneous
expression of both markers vs cases with only one or neither. 0,
bcl-2+, p53+; x, bcl-2-l', p53-/+.
relationship with overall survival. These results failed to
confirm those obtained by Yunis et al. (1989), which suggest
that in follicular lymphomas with a large-cell component the
presence of a (14;18) translocation is associated with a poor
prognosis. However, differences in the selection of cases and
in the technique for demonstrating bcl-2 activation may ex-
plain some of the differences found.
p53 expression in this group of patients is found in similar
percentages in lymphomas of mucosa and nodal origin, and
is more frequent in Burkitt cases. The relation between p53
expression and overall survival in our series is significant,
independently of histological diagnosis, and is perhaps relat-
ed to treatment failure, since p53-positive patients show a
sudden decrease in life expectancy during the first months
after diagnosis. Multivariant regression analysis findings are
in agreement with these results. They confirm that the only
parameters significantly related with survival are extranodal
origin, which is associated with a better prognosis, and p53
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The relationship between p53 expression and low survival
rates has also been found in other types of tumours (Thor et
al., 1992; Visakorpi et al., 1992). This has been suggested for
lymphomas (Levine et al., 1988; Cabanillas et al., 1989;
Schouten et al., 1990; Rodriguez et al., 1991), based on
cytogenetic studies. Significantly, Cabanillas et al. (1989) des-
cribed a strikingly high rate of refractoriness to chemo-
therapy in patients with chromosome 17 alterations. This is
similar to the early strong decrease in life expectancy for the
p53+ patients in our series. An association between multi-
drug resistance protein (MDR) and p53 protein has in fact
been proposed, since mutant p53 may stimulate MDR1 pro-
moter, and wild-type p53 could exert specific repression
(Chin et al., 1992). This MDR activation could explain the
absence of chemotherapeutic response in p53+ patients.
Recent findings about the role of p53 gene suggest new
possibilities for explaining the speedier progression of p53+
tumours. Different groups have shown p53 levels to increase
after genotoxic injury, this high level of p53 protein being
related to the capacity of cells with DNA damage to undergo
apoptosis (Clarke et al., 1993; Fritsche et al., 1993; Hall et
al., 1993; Lowe et al., 1993). This may imply that cells with
inactivation of one or both p53 alleles (consequently lacking
this mechanism of programmed cell death induction) could
have a survival advantage over those without p53 alterations.
The range of p53 expression detected in this series of NHLs
may be a common final consequence of different ways of
genetic inactivation. In fact, p53 detection by immunohisto-
logical techniques has been described as the consequence of
protein stabilisation dependent on a conformational change
from wild-type to mutant-type protein (Milner & Medcalf,
1991). While the wild-type p53 protein has a suppressor role
in the control of the cell cycle, mutant p53 protein may have
the opposite effect, inducing cell growth (Finlay et al., 1988;
Hinds et al., 1989; Lane & Benchimol, 1990). Mutation of
the p53 gene or conformational change in the p53 protein
secondary to other causes may constitute a key step in some
lymphomas, allowing further tumour expansion, as has been
found in other human tumours (Sidransky et al., 1992).
The combined expression of bcl-2 and p53 identifies
tumours with a poorer prognosis than those expressing p53
only. This is particularly significant for cases of large B-cell
lymphoma presenting in lymph node. This poorer prognosis
seems to be dependent on the accumulation of both bcl-2 and
p53 expression rather than the interaction between them.
However, comparative analysis between the groups of bcl-2+,
p53+ lymphomas vs bcl-2-, p53+ is difficult because of the
small number of cases included in both groups and the short
follow-up of the bcl-2-, p53+ group. This prevents the detec-
tion of significant differences. A longer follow-up of a larger
group of lymphoma patients could indicate the specific
impact of each marker on survival.
The cumulative poor effect of both p53 and bcl-2 in large
B-cell lymphomas, which is more significant in nodal
tumours, could confirm the existence of multiple gene
deregulation in non-Hodgkin's lymphoma. This would take
place in a multistep pattern similar to that described in
colorectal cancer (Fearon & Vogelstein, 1990) and would
address the genetic mechanisms of apoptosis control and
their disregulation as critical steps in the progression of
tumours.
p53 expression could be tested for in NHLs, as a cheap
and reproducible way of identifying patients with a poor
prognosis. p53+ tumours could be candidates for more inten-
sive therapy, or different therapeutic approaches.
The work was supported by a grant from the Fondo de Investi-
gaciones Sanitarias (FIS), Spain, and by the Leukaemia Research
Fund, UK. F. Pezzella is a Leukaemia Research Fund research
fellow. Thanks to Isabel Galvez, Alicia Mufioz, Margaret Jones,
Helen Turley and Heather Morrison for their excellent technical
assistance.
References
AISENBERG, A.C., WILKES, B.M. & JACOBSON, J.O. (1988). The bcl-2
gene is rearranged in many diffuse B-cell lymphomas. Blood, 71,
969-972.
BANKS, S.J., MATLASHEWISKI, G. & CRAWFORD, L. (1986). Isola-
tion of human p53 specific monoclonal antibodies and their use
in the studies of human p53 expression. Eur. J. Biochem., 159,
529-534.
CABANILLAS, F., PATHAK, S., GRANT, G., HAGEMEISTER, F.B.,
McLAUGHLIN, P., SWAN, F., RODRIGUEZ, M.A., TRUJILLO, J.,
CORK, A., BUTLER, J.J., KATZ, R., BOURNE, S. & FREIREICH,
E.J. (1989). Refractoriness to chemotherapy and poor survival
related to abnormalities of chromosome 17 and 7 in lymphoma.
Am. J. Med., 87, 167-172.
CESERMAN, E., CHADBURN, A., INGHIRAMI, G., GAIDANO, G. &
KNOWLES, D. (1992). Structural and functional analysis of onco-
genes and tumour suppressor genes in adult T-cell leukemia/
lymphoma shows frequent p53 mutations. Blood, 80, 3205-
3216.
CHIN, K.V., UEDA, K., PASTAN, I. & GOTTESMAN, M.M. (1992).
Modulation of activity of the promotor of the human MDR1
gene by Ras and p53. Science, 255, 459-462.
CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD,
C.C., HOOPER, M.L. & WYLLIE, A.H. (1993). Thymocyte apopto-
sis induced by p53-dependent and independent pathways. Nature,
362, 849-852.
COIFFIER, B., GISSELBRECHT, C., VOSE, J.M., TILLY, H., HERB-
RECHT, R., BOSLY, A. & ARMITAGE, J.O. (1991). For the groupe
d'Etudes des Lymphomes agressifs. Prognostic factors in aggres-
sive malignant lymphomas: description and validation of a pro-
gnostic index that could identify patients requiring a more inten-
sive therapy. J. Clin. Oncol., 9, 211-219.
CORDELL, J.L., FALINI, B., ERBER, W.N., ABDULAZIZ, Z., MAC-
DONALD, S., PULFORD, K.A.F., STEIN, H. & MASON, D.Y. (1984).
Immunoenzymatic labelling of monoclonal antibodies using
immune complexes of alkaline phosphatase and monoclonal anti-
alkaline phosphatase (APAAP complex). J. Histochem. Cyto-
chem., 32, 219-222.
COX, D.R. (1972). Regression models and life tables. J. R. Stat. Soc.,
34, 187-220.
DOGLIONI, C., PELOSIO, P., MOMBELLO, A., SCARPA, A. & CHILOSI,
M. (1991). Immunohistochemical evidence of abnormal expres-
sion of the antioncogene-encoded p53 phosphoprotein in Hodg-
kin's disease and CD30+ anaplastic lymphomas. Hematol.
Pathol., 5, 67-73.
FANIDI, A., HARRINGTON, E.A. & EVAN, G.I. (1992). Cooperative
interaction between c-myc and bcl-2 proto-oncogenes. Nature,
359, 554-556.
FARRELL, P.J., ALLAN, G.J., SHANAHAN, F., VOUSDEN, K.H. &
CROOK, T. (1991). p53 is frequently mutated in Burkitt's lym-
phoma cell lines. EMBO J., 10, 2879-2887.
FEARON, E.R. & VOGELSTEIN, B. (1990). A genetic model for colo-
rectal tumorigenesis. Cell, 61, 759-767.
FINKE, J., FRITZEN, R., TERNES, P., TRIVEDI, P., BROSS, K.J.,
LANGE, W., MERTELSMANN, R. & DOLKEN, G. (1992). Expres-
sion of bcl-2 in Burkitt's lymphoma cell lines: induction by latent
Epstein-Barr virus genes. Blood, 80, 459-469.
FINLAY, C.A., HINDS, P.W., TAN, T.H., ALIYAHU, D., OREN, M. &
LEVIN, J. (1988). Activating mutations for transformation by p53
produce a gene produce that forms hsc70-p53 complex with an
altered half life. Mol. Cell. Biol., 8, 531-539.
FRITSCHE, M., HAESSLER, C. & BRANDNER, G. (1993). Induction of
nuclear accumulation of the tumor-suppressor protein p53 by
DNA-damaging agents. Oncogene, 8, 307-318.
GAIDANO, G., BALLERINI, P., GONG, J.Z., INGHIRAMI, G., NERI, A.,
NEWCOMB, E.W., MAGRATH, I.T., KNOWLES, D.M. & DALLA-
FAVERA, R. (1991). p53 mutations in human lymphoid malignan-
cies: association with Burkitt lymphoma and chronic lymphocytic
leukemia. Proc. Nati. Acad. Sci. USA, 88, 5413.
HALL, P.A., MCKEE, P.H., MENAGE, H.P., DOVER, R. & LANE, D.P.
(1993). High levels of p53 in UV-irradiated normal human skin.
Oncogene, 8, 203-207.p53 AND bcl-2 EXPRESSION IN LYMPHOMA 341
HENDERSON, S., ROWE, M., GREGORY, C., CROOM-CARTER, D.,
WANG, F., LONGNECKER, R., KIEFF, E. & KICKINSON, A.
(1991). Induction of bcl-2 expression by Epstein-Barr virus latent
membrane protein I protects infected B cells from programmed
cell death. Cell, 65, 1107-1115.
HINDS, P.W., FINLAY, C.A., LEVINE, A.J. (1989). Mutation is
required to activate the p53 gene for cooperation with the ras
oncogene and transformation. J. Virol., 63, 739-746.
HOCKENBERRY, D., NUNEZ, G., MILLIMAN, C., SCHEREIBER, R.D.
& KORSMEYER, S.J. (1990). bcl-2 is an inner mitochondrial mem-
brane protein that blocks programmed cell death. Nature, 348,
334-336.
ICHIKAWA, A., HOTTA, T., TSUSHITA, K., KINOSHITA, T., NAGAI,
H., MURAKAMI, Y., HAYASHI, K. & SAITO, H. (1992). Mutations
of p53 gene and their relation to disease progression in B-cell
lymphoma. Blood, 79, 2701-2707.
KAPLAN, E.L. & MEIER, P. (1958). Non-parametric estimation from
incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
LANE, D., BENCHIMOL, S. (1990). Oncogene or anti-oncogene?
Genes Dev., 4, 1-3.
LENNERT, K. & FELLER, A.C. (1990). Non-Hodgkin-Lymphome
(nach der aktualisierten Kiel-Klassifikation). Springer: Berlin.
LEVINE, E.G., ARTHUR, D.C., FRIZZERA, G., PETERSON, B.A.,
HURD, D.D. & BLOOMFIELD, C.D. (1988). Cytogenetic abnor-
malities predict clinical outcome in non-Hodgkin lymphoma.
Ann. Intern. Med., 108, 14-20.
LOWE, S.W., SCHMITT, E.M., SMITH, S.W., OSBORNE, B.A. & JACKS,
T. (1993). p53 is required for radiation-induced apoptosis in
mouse thymocytes. Nature, 362, 847-849.
MILNER, J. & MEDCALF, E.A. (1991). Cotranslation of activated
mutant p53 with wild type drives the wild-type p53 protein into
the mutant conformation. Cell, 65, 765-774.
PETO, R., ROE, F.J.C., LEE, P.N., LEVY, L. & CLACK, J. (1975).
Cancer and ageing in mice and men. Br. J. Cancer, 32,
411-426.
PEZZELLA, F., TSE, A.G.D., CORDELL, J.L., PULFORD, K.A.F., GAT-
TER, K.C. & MASON, D.Y. (1990). Expression of the bcl-2
oncogene protein is not specific for the 14;18 chromosomal trans-
location. Am. J. Pathol., 137, 225-232.
PEZZELLA, F., JONES, M., RALFKIAER, E., ERSBOLL, J., GATTER,
K.C. & MASON, D.Y. (1992). Evaluation of bcl-2 protein expres-
sion and 14;18 translocation prognostic markers in follicular
lymphoma. Br. J. Cancer, 65, 87-89.
PEZZELLA, F., MORRISON, H., JONES, M., GATTER, K.C., LANE, D.,
HARRIS, A.L. & MASON, D.Y. (1993). Immunohistochemical
detection of p53 and bcl-2 protein in non-Hodgkin's lymphoma.
Histopathology, 22, 39-44.
RAGHOEBIER, S., KRAMER, M.H.H., VAN KRIEKEN, J.H.J.M., DE
JONG, D., LIMPENS, J., KLUIN-NELEMANS, J.C., VAN OMMEN,
G.J.B. & KLUIN, PH. M. (1991). Essential differences in oncogene
involvement between primary nodal and extranodal large cell
lymphoma. Blood, 78, 2680-2685.
RODRIGUEZ, M.A., FORD, R.J., GOODACRE, A., SELVANAYAGAM,
P., CABANILLAS, F. & DEISSEROTH, A.B. (1991). Chromsome
17p and p53 changes in lymphoma. Br. J. Haematol., 79,
575-582.
SCHOUTEN, H.C., SANGER, W.G., WEISENBURGER, D.D., ANDER-
SON, J. & ARMITAGE, J.O. (1990). Chromosomal abnormalities in
untreated patients with non-Hodgkin's lymphoma: associations
with histology, clinical characteristics, and treatment outcome.
Blood, 75, 1841-1847.
SETO, M., JAEGER, U., HOCKETT, R.D., GRANINGER, W., BENNETT,
S., GOLDMAN, P. & KORSMEYER, S.J. (1988). Alternative pro-
moters and exons, somatic mutation and deregulation of the
bcl-2-Ig fusion gene in lymphoma. EMBO J., 7, 123-131.
SIDRANSKY, D., MIKKELSEN, T., SCHWECHHEIMER, K., ROSENB-
LUM, M.L., CAVANEE, W. & VOGELSTEIN, B. (1992). Clonal
expansion of p53 mutant cells is associated with brain tumour
progression. Nature, 355, 846-847.
THOR, A.D., MOORE, D.H., EDGERTON, S.M., KAWAASAKI, E.S.,
REIHSAUS, E., LYNCH, H.T., MARCUS, J.N., SCHWARTZ, L.,
CHEN, L.L., MAYALL, B.H. & SMITH, H.S. (1992). Accumulation
of p53 tumour suppressor gene protein: an independent marker
of prognosis in breast cancers. J. Natl Cancer Inst., 84,
845-855.
VELASQUEZ, W.S., JAGANNATH, S., TUCKER, S.L., FULLER, L.M.,
NORTH, L.B., REDMAN, J.R., SWAN, F., HAGEMEISTER, F.B.,
McLAUGHLIN, P. & CABANILLAS, F. (1989). Risk classification
as the basis for clinical staging of diffuse large cell lymphoma
derived from 10-year survival data. Blood, 74, 551-557.
VILLUENDAS, R., PIRIS, M.A., ORRADRE, J.L., MOLLEJO, M., ROD-
RIGUEZ, R. & MORENTE, M. (1991). Different bcl-2 protein ex-
pression in high-grade B-cell lymphomas derived from lymph
node or mucosa-associated lymphoid tissue. Am. J. Pathol., 139,
989-993.
VILLUENDAS, R., PIRIS, M.A., ORRADRE, J.L., MOLLEJO, M.,
ALGARA, P., SANCHEZ, L., MARTINEZ, J.C. & MARTINEZ, P.
(1992). p53 protein expression in lymphomas and reactive lym-
phoid tissue. J. Pathol., 166, 235-241.
VISAKORPI, T., KALLIONEMI, O.P., HEIKKINEN, A., KOIVULA, T. &
ISOLA, J. (1992). Small subgroup of aggressive, highly proli-
ferative prostatic carcinomas defined by p53 accumulation. J.
Natl Cancer Inst., 84, 883-887.
WIMAN, K.G., MAGNUSSON, K.P., RAMQUIST, T. & KLEIN, G.
(1991). Mutant p53 detected in a majority of Burkitt lymphoma
cell lines by monoclonal antibody PAb240. Oncogene, 6, 1633-
1639.
YUNIS, J.J., MAYER, M.G., ARNESEN, M.A., AEPPLI, D.P., OKEN,
M.M. & FRIZZERA, G. (1989). bcl-2 and other genomic alterations
in the prognosis of large-cell lymphoma. N. Engl. J. Med., 320,
1047-1054.
ZUTTER, M., HOCKENBERRY, D., SILVERMAN, G.A. & KORS-
MEYER, S.J. (1991). Immunolocalization of the bcl-2 protein
within haematopoietic neoplasms. Blood, 78, 1062-1068.